We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · December 02, 2021

Clinical Factors Associated With Long-Term Benefit in Patients With mRCC Treated With Axitinib

Clinical Genitourinary Cancer


Additional Info

Clinical Genitourinary Cancer
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clin Genitourin Cancer 2021 Oct 20;[EPub Ahead of Print], Á Pinto, O Reig, C Iglesias, E Gallardo, X García-Del Muro, T Alonso, G Anguera, C Suárez, J Muñoz-Langa, L Villalobos-León, Á Rodríguez-Sánchez, N Lainez, E Martínez-Ortega, M Campayo, A Velastegui, A Rodriguez-Vida, JC Villa-Guzmán, MJ Méndez-Vidal, G Rubio, I García, L Capdevila, J Lambea, S Vázquez, O Fernández, S Hernando-Polo, S Cerezo, C Santander, R García-Marrero, F Zambrana, A González-Del Alba, M Lazaro-Quintela, D Castellano, I Chirivella, U Anido, A Viana, A García, M Sotelo, MG Arévalo, J García-Donas, C Hernández, MV Bolós, J Llinares, MA Climent

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading